Keywords
> MYOBASE > HEALTH > medicine > disease > disease by system > locomotor system diseases > neuromuscular disease > neuromuscular disease by clinic > idiopathic inflammatory myopathy > dermatomyositis
dermatomyositisSee also: |
Documents disponibles dans cette catégorie (649)
sorted by (Issue date descending, Issue date descending, System of projection of the document ascending) | Add the result to the basket | Make a suggestion | Refine your search
Extend search on down-posting(s)
Article
Yeker RM, Author ; Pinal Fernandez I ; Kishi T ; Pak K ; Targoff IN ; Miller FW ; Rider LG ; Mammen AL | 23/01/2018Article
Deakin CT, Author ; Campanilho-Marques R ; Simou S ; Moraitis E ; Wedderburn LR ; Pullenayegum E ; Pilkington CA | accepted | 17/01/2018Article
Tjärnlund A, Author ; Tang Q ; Wick C ; Dastmalchi M ; Mann H ; Tomasová Studýnková J ; Chura R ; Gullick NJ ; Salerno R ; Rönnelid J ; Alexanderson H ; Lindroos E ; Aggarwal R ; Gordon P ; Vencovsky J ; Lundberg IE | 2018Article
McCann LJ, Author ; Pilkington CA ; Huber AM ; Ravelli A ; Appelbe D ; Kirkham JJ ; Williamson PR ; Aggarwal A ; Christopher Stine L ; Constantin T ; Feldman BM ; Lundberg I ; Maillard S ; Mathiesen P ; Murphy R ; Pachman LM ; Reed AM ; Rider LG ; van Royen-Kerkof A ; Russo R ; Spinty S ; Wedderburn LR ; Beresford MW | 2018Comment in: Standardising measures in pediatric rheumatology: the experience of the international consensus dataset for juvenile dermatomyositis. [Ann Transl Med. 2018]Article
Aeschlimann FA, Author ; Aeschlimann FA ; Fremond ML ; Duffy D ; Rice GI ; Charuel JL ; Bondet V ; Saire E ; Neven B ; Bodemer C ; Balu L ; Gitiaux C ; Crow YJ ; Bader-Meunier B | 2018Comment in: Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. [Brain. 2018] Comment on: JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. [Brain. 2018]Article
Allenbach Y, Author ; Allenbach Y ; Toquet S ; Landon-Cardinal O ; Benveniste O | 2018Comment on: JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. [Brain. 2018] A child with severe juvenile dermatomyositis treated with ruxolitinib. [Brain. 2018]Article
Ladislau L, Author ; Suarez-Calvet X ; Toquet S ; Landon-Cardinal O ; Amelin D ; Depp M ; Rodero MP ; Hathazi D ; Duffy D ; Bondet V ; Preusse C ; Bienvenu B ; Rozenberg F ; Roos A ; Benjamim CF ; Gallardo E ; Illa I ; Mouly V ; Stenzel W ; Butler Browne G ; Benveniste O ; Allenbach Y | 2018Comment in: Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. [Brain. 2018] A child with severe juvenile dermatomyositis treated with ruxolitinib. [Brain. 2018]Article
Best M, Author ; Jachiet M ; Molinari N ; Manna F ; Girard C ; Pallure V ; Cosnes A ; Lipsker D ; Hubiche T ; Schmutz JL ; Le Corre Y ; Cordel N ; Dandurand M ; Dereure O ; Guillot B ; Du-Thanh A ; Bulai Livideanu C ; Chasset F ; Bouaziz JD ; Frances C ; Bengoufa D ; Vincent T ; Bessis D | 2018Article
Rider LG, Author ; Aggarwal R ; Machado PM ; Hogrel JY ; Reed AM ; Christopher Stine L ; Ruperto N | 2018Article
Article
Aouizerate J, Author ; De Antonio M ; Bader-Meunier B ; Barnerias C ; Bodemer C ; Isapof A ; Quartier P ; Melki I ; Charuel JL ; Bassez G ; Desguerre I ; Gherardi RK ; Authier FJ ; Gitiaux C | 2018Article
Umezawa N, Author ; Kawahata K ; Mizoguchi F ; Kimura N ; Yoshihashi-Nakazato Y ; Miyasaka N ; Kohsaka H | 2018Article
Schiffenbauer A, Author ; Garg M ; Castro C ; Pokrovnichka A ; Joe G ; Shrader J ; Cabalar IV ; Faghihi-Kashani S ; Harris-Love MO ; Plotz PH ; Miller FW ; Gourley M | 2018